Anika Therapeutics, Inc. PondelWilkinson Inc. Charles H. Sherwood, Ph.D., CEO Rob Whetstone (310) 279-5963 Kevin W. Quinlan, CFO Wade Huckabee (310) 279-5971 (781) 932-6616

THERAPEUTICS ANNOUNCES ADDITION OF

WOBURN, Mass. July 12, 2005 Anika Therapeutics,

Inc. (NASDAQ:ANIK) today announced

it has appointed Kevin W. Quinlan as chief financial officer.

We are pleased to have strengthened the Anika

Therapeutics management team with a seasoned executive such as Mr. Quinlan,

said Charles Sherwood, Ph.D., president and chief executive officer. He brings

a wealth of knowledge to Anika and we are certain he will make an immediate

contribution to our organization.

Quinlan, 55, is a Certified

Public Accountant and brings to Anika more than 30 years of experience in the

financial and biotechnology industries. He joins the company from Boston

Biomedica, Inc., a provider of products and services to the diagnostics, life

sciences and pharmaceutical industries. He joined Boston Biomedica as chief

financial officer in 1993 and served, most recently, as president of its BBI

Diagnostics division. From 1990 to 1993, Quinlan served as chief financial

officer for Parctec Inc., a sales and finance consulting subsidiary of Kleinwort

Benson Group. Prior to Parctec, Quinlan worked as audit supervisor at the

public accounting firm Coopers & Lybrand. Quinlan earned his Master of

Science degree in accounting from Northeastern University and his Bachelor of Science

degree in resource economics from the University of New Hampshire.

About Anika Therapeutics, Inc.

in Woburn, Mass., Anika Therapeutics, Inc. (www.anikatherapeutics.com)

develops, manufactures and commercializes therapeutic products and devices

intended to promote the repair, protection and healing of bone, cartilage and

soft tissue. These products are based on hyaluronic acid (HA), a naturally

occurring, biocompatible polymer found throughout the body. Anika products include

OrthoVisc , a treatment for osteoarthritis of the knee available

internationally and marketed in the U.S. by Ortho Biotech Products, L.P., and

Hyvisc , a treatment for equine osteoarthritis marketed in the U.S.

by Boehringer Ingelheim Vetmedica, Inc. Anika manufactures Amvisc

HA viscoelastic products for ophthalmic surgery. It also produces CoEase ,

which is marketed by Advanced Medical Optics, Inc., STAARVISC -II

distributed by STAAR Surgical Company and Shellgel for Cytosol

statements made in this press release which are not statements of historical

fact are forward-looking statements within the meaning of Section 27A of the

Securities Act of 1933 and Section 21E of the Securities Exchange Act of

1934. Forward-looking statements involve known and unknown risks,

uncertainties and other factors. The words will, seek, and other

expressions which are predictions of or indicate future events and trends and

which do not constitute historical matters, such as statement regarding the

expectations of performance of the Company s chief financial officer, identify

forward-looking statements. All statements, other than statements of

historical facts, are forward-looking statements based in the current beliefs

and assumptions of management and are subject to significant risks and

uncertainties. The Company s actual results could differ materially from

any anticipated future results, performance or achievements described in the

forward-looking statements as a result of a number of factors, including the

risk that the Company s efforts to enter into long-term strategic relationships

will not be successful or that the Company does not achieve any additional or

significant sales from such relationships and the risk that the Company is

unable to expand its product portfolio and revenue base to the extent

intended. Certain other factors that might cause the Company actual

results to differ materially from those in the forward-looking statements

include those set forth under the headings Business, Risk Factors and

Certain Factors Affecting Future Operating Results and Management s

Discussion and Analysis of Financial Condition and Results of Operations in

each of the Company s Annual Report on Form 10-K for the year ended December

31, 2004, Quarterly Report on Form 10-Q for the quarter ended March 31,

2005, and Current Reports on Form 8-K, as well as those described in the

Company s other press releases and SEC filings.